期刊
IMMUNOTHERAPY
卷 6, 期 7, 页码 833-852出版社
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.14.51
关键词
adoptive cell transfer; cancer immunotherapy; cancer vaccine; CD8(+) T-cell checkpoint blockade; chimeric antigen receptor; lymphodepletion; tolerance
类别
资金
- NIH/National Institute of Allergy and Infectious Disease [R01AI087764]
- Cancer Research Institute
- NIH/National Cancer Institute [F30CA180375]
In the final issue of Science in 2013, the American Association of Science recognized progress in the field of cancer immunotherapy as the 'Breakthrough of the Year.' The achievements were actually twofold, owing to the early success of genetically engineered chimeric antigen receptors (CAR) and to the mounting clinical triumphs achieved with checkpoint blockade antibodies. While fundamentally very different, the common thread of these independent strategies is the ability to prevent or overcome mechanisms of CD8(+) T-cell tolerance for improved tumor immunity. Here we discuss how circumventing T-cell tolerance has provided experimental insights that have guided the field of clinical cancer immunotherapy to a place where real breakthroughs can finally be claimed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据